DRPevader: Ex vivo-diagnosis and prognosis of early diabetic retinopathy
A novel ex vivo method for immediate early diagnosis and prognosis of proliferative diabetic retinopathy (DRP) is provided with DRPevader.
DRPevader is based on the analysis of expression and activity of very few genes which can simply be determined using whole blood or a blood component. Therefore, DRPevader is the diagnostic link between the alteration of leukocyte gene expression, the activity of specific serum-markers, and proliferative DRP.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
